about
Aspirin improves outcome in high risk prostate cancer patients treated with radiation therapy.A Phase I Dose-Escalation Trial of Single-Fraction Stereotactic Radiation Therapy for Liver MetastasesPretreatment biopsy analysis of DAB2IP identifies subpopulation of high-risk prostate cancer patients with worse survival following radiation therapyKey role for neutrophils in radiation-induced antitumor immune responses: Potentiation with G-CSF.Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study.Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment.Anatomical patterns of recurrence following biochemical relapse after post-prostatectomy salvage radiation therapy: a multi-institutional study.Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer.Stereotactic body radiation therapy for low and intermediate risk prostate cancer-Results from a multi-institutional clinical trial.Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus.Hypofractionated whole-breast radiation therapy: does breast size matter?A new method to reconstruct intra-fractional prostate motion in volumetric modulated arc therapy.PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression.Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.Dosimetric comparison of rectal-sparing capabilities of rectal balloon vs injectable spacer gel in stereotactic body radiation therapy for prostate cancer: lessons learned from prospective trials.Reliable gene mutation prediction in clear cell renal cell carcinoma through multi-classifier multi-objective radiogenomics modelFully automated organ segmentation in male pelvic CT imagesEffect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 TrialStereotactic Radiosurgery for Multiple Brain Metastases From Renal-Cell Carcinoma.Timing of postseed imaging influences rectal dose-volume parameters for cesium-131 prostate seed implantsAn Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory FactorsSafety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapyTumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomesImproved Survival Outcomes for Kidney Cancer Patients With Brain MetastasesReply to Francesco Montorsi, Alessandro Larcher, and Umberto Capitanio's Letter to the Editor re: Rohann J.M. Correa, Alexander V. Louie, Nicholas G. Zaorsky, et al. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell CarcIncidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry StudyImpact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical FailureStereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell CancerPD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab responseAddition of Iodinated Contrast to Rectal Hydrogel Spacer to Facilitate MRI-Independent Target Delineation and Treatment Planning for Prostate CancerThe Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-AnalysisEditorial Comment
P50
Q33727848-4FE1515A-66C3-43D6-B17E-759F1FF32BB3Q36415438-9454212A-CA88-43BA-9A71-537158C89F7FQ37084855-3017216D-756F-40D8-AA2D-F6D89C42F577Q37322905-05575951-A1C1-401F-AB1F-401237BE3068Q38674757-247054D2-5576-407A-8076-1D10849F6653Q38740530-E6A7A116-42CC-4F4B-BD1A-1C41E0D31139Q38981347-7822444B-C374-41C6-98F7-AA471DF7ADDAQ38990477-757164BE-D1CD-4FC0-9E0C-CA57DC590878Q39096419-1BC3784A-3493-4DEE-AA7F-207583C7C8D4Q39340402-7A8068D8-F13C-4A7B-9234-5014C4200403Q39872066-57B8F46B-F082-48F8-8709-FE2AD2EB8430Q42148457-1F5ABC9C-1501-4D7E-AFF5-1361155AAB94Q47313016-6B23ABC3-E456-40A8-9137-3F078AD404B8Q48023240-CC2FBA00-772E-4D39-B0C0-07DCB93FABF2Q50031872-85FB24CC-189B-4708-8B67-B088A5B68F91Q50605072-9C8DFB7F-B19D-4809-973C-7D254B0D324AQ53126646-86160F4D-1FF0-4E60-B482-FD531251F6C1Q57049453-91A460C8-86CE-4ED9-A473-DAF2E675146CQ62492416-FD015C36-A5DB-4091-BECC-EA82A0100CB1Q64113667-7F87958E-4525-4415-9A33-88FA62334BEFQ64913810-D3BE3952-F6E3-463B-8424-7836FE0D3699Q84830249-935DE970-B909-41C9-BC69-DAE252FBEC0CQ89047103-1B045CAC-862A-4589-9ED8-F09D6019A53BQ89097028-E18AA234-DBB7-4AAF-8518-2D179F402B99Q89838032-AE9F946D-B950-4A45-94AD-ABF7D69EC337Q90410649-58ADDACA-2FAD-438D-8C0C-01D0B4B2CE01Q91077179-45410952-BACA-4453-B158-4FF6C29BBEDFQ91456640-3EE6DD35-9FA3-4363-AFB0-8B7E745A45B1Q92114397-92F402C9-276B-40EB-A205-CE8ACB0FBACDQ92385955-AA647CBE-802F-413F-82F1-72E6371A7022Q92469621-A41C3C4B-2B08-4552-8BC6-519027514106Q92586747-DB306D4A-08D7-4D2F-9239-E048720B38D7Q93086128-1D759805-8130-44AA-A883-A269CC57F820Q95380839-7522FC7F-74ED-4A5A-AEDA-2256423F6933
P50
description
researcher ORCID ID = 0000-0003-1282-056X
@en
wetenschapper
@nl
name
Raquibul Hannan
@ast
Raquibul Hannan
@en
Raquibul Hannan
@es
Raquibul Hannan
@nl
type
label
Raquibul Hannan
@ast
Raquibul Hannan
@en
Raquibul Hannan
@es
Raquibul Hannan
@nl
prefLabel
Raquibul Hannan
@ast
Raquibul Hannan
@en
Raquibul Hannan
@es
Raquibul Hannan
@nl
P106
P31
P496
0000-0003-1282-056X